Platform Adaptive trial of NOvel antiviRals for eArly treatMent of covid-19 In the Community (PANORAMIC)
Despite high uptake of vaccination against COVID-19, the disease remains prevalent in the UK and in many countries around the world, with many patients continuing to experience considerable morbidity and require treatment in hospital. There is therefore an urgent need to identify treatments for COVID-19 for use in the community early on in the illness that speeds recovery and prevents the need for hospital admission.
The primary aim of the main trial is to determine the effectiveness of selected antiviral agents in preventing hospitalisation and/or death in higher-risk patients with a confirmed positive SARS-CoV-2 PCR or lateral flow test result. A prospective economic evaluation is also embedded within the trial design to assess the cost effectiveness of each antiviral.